ENABLE Biotech has been featured in Cell & Gene Therapy Review
alongside big players in the dynamic Swiss CGT ecosystem

READ

The new Swiss CDMO offering phase-appropriate CMC expertise at an attractive cost

Services

Finding the right partner for First in Human production can be challenging.

ENABLE BIOTECH IS THE RIGHT PARTNER

We address specific challenges of manufacturing advanced therapies.

Learn more about how ENABLE BioTech can become YOUR next generation CDMO.

CMC EXPERTISE
Team with specific expertise and capabilities in the field of CGT manufacturing, ensuring a smooth transition of manufacturing processes
FLEXIBILITY
Transparent collaboration on developing manufacturing and QA process, providing flexibility for future in-house production
SPEED
Available capacity in SwissMedic accredited GMP facility R&D and manufacturing suites, avoiding delays to First in Human
AFFORDABILITY
Attractive costs for affordable therapies through use of existing SwissMedic accredited GMP facility

Service Offerings for Cell & Gene Therapy

Production of Cell Therapies, Gene-Modified Cell Therapies, and Exosome Therapies

Utilizing various cell types including PBMC (T Cells, NK cells, Invariant NK Cells) iPSC, MSC, HLSC, and more

Gene editing using viral vectors (AAV, LVV) or electroporation

Preparation of CMC sections in regulatory submissions, anticipating increasing clinical development requirements

„>“>Value Proposition

Focus on client needs & Tailored Services
Access to wealth of experience in the ENABLE Biotech network (QC, RA, QP, QA (beyond normal routine), CMC, Engineering
Novel Operating Model permitting efficient work execution and attractive pricing in sync with early-stage clinical client needs

Focusing only on the needs of clinical stage companies pursuing a phase-adapted approach towards compliance, Enable Biotech has established an innovative setup for development and clinical manufacturing capacity, capabilities, and resources enabling a very attractive pricing structure.

With its network and team of highly qualified experts in the field that support special activities (RA, QP, QA (beyond normal routine), CMC, Engineering) ad hoc on demand to reduce basic operation costs while keeping access to their valuable knowledge, Enable Biotech is best positioned to ensure project realization that incorporates closely the project sponsor while providing guidance and making the wealth of existing experience available / accessible.

„>“>Infrastructure

Premises

Development laboratory of (35 m2, CNC)
GMP Production Room (45m2, Grade C) equipped with 3x Grade A Isolators
QC Laboratories (45m2, CNC) for QC-release testing and Environmental Monitoring

Key Equipment

CliniMACS PLUS® & Prodigy® Automated Cell Processing Closed Systems
Lovo® Automated Cell Processing System
G-Rex® (Gas Permeable Rapid Expansion) Platform
ExoView™ R100 for Complete Extracellular Vesicle Characterization
CTS™ DynaBeads System for Ex Vivo Isolation, Activation, & Expansion of T-Cells
Vi-Cell BLU Cell Viability Analyzer
NTA Exosome Counter
The Exoid TRPS System for Nanoparticle Characterization

About Us

Enable Biotech Ltd, founded in 2023 in Zug, Switzerland, is offering innovative custom fee for service activities in the development and clinical manufacturing of Cell & Gene Therapies (ATMPs) and Exosome Therapies.
As part of its service offering, Enable Biotech offers clinical GMP mancufacturing activities for Cell Therapies and Exosome Therapies and as of Summer 2024 clinical GMP manufacturing activities for Gene Therapies (awaiting accreditation by SwissMedic).

Alain Pralong

Chief Executive Officer

PhD in Molecular & Cell Biology

Yves Maag

Chief Operating Officer

Renaud Jacquemart

Chief Commercial Officer

MBA, PhD in Chemical Engineering

News

Contact

Enable Biotech Ltd.
Baarerstrasse 8
6300 Zug